Clinical Trial News and Research

RSS

Cohera Medical reports top-line results from Tissuglu clinical trial

Cohera Medical, Inc.® today announced that top-line clinical study results demonstrate the safety and preliminary effectiveness of the company's lead surgical adhesive product, TissuGlu®.

6 May 2010

CSI fiscal third-quarter revenue increases 9% to $16.5 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.

6 May 2010

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2010, and provided an update with respect to the Company's key business initiatives.

6 May 2010

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Genomic Health, Inc. today reported financial results and business progress for the quarter ended March 31, 2010.

6 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Pharmacyclics, Inc. today reported financial results for its third quarter ended March 31, 2010.

6 May 2010

Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416

Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.

6 May 2010

Jazz Pharmaceuticals reports 59% increase in first-quarter 2010 revenue

Jazz Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2010 and updated guidance for sales and expenses for 2010.

6 May 2010

GeoVax Labs reports net loss of $690,789 for first-quarter 2010

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for the three months ended March 31, 2010.

6 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

Cardiogenesis reports 13% increase in first-quarter 2010 revenue

Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of cardiac patients suffering from severe angina, today reported financial results for its first quarter ended March 31, 2010.

6 May 2010

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.

6 May 2010

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).

5 May 2010

Rockwell Medical first-quarter sales up 17.1%

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported first quarter 2010 results today.

5 May 2010

STEM reports net loss of $6,124,000 for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring StemCells Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

5 May 2010

BioClinica reports service revenues of $14,746,000 for first-quarter 2010

BioClinica, Inc., a global provider of clinical trial management services, today announced its financial results for the first quarter ended March 31, 2010.

From Clario 5 May 2010

Canadian Cancer Society awards London scientists new funds for innovative research

Three London scientists are receiving new funding from the Canadian Cancer Society for their work in innovative cancer research.

5 May 2010

Three Hamilton scientists receive cancer research grants from Canadian Cancer Society

Three Hamilton scientists are receiving new funding from the Canadian Cancer Society for their work in innovative cancer research.

5 May 2010

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.

5 May 2010

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

An estimated 26.2 percent of Americans ages 18 and older - about one in four adults - suffer from a diagnosable mental disorder every year, which equates to approximately 57.7 million adults. Severe psychiatric illness affects a much smaller number of people - about 6 percent, or 1 in 17. Worldwide, an estimated 340 million people suffer from an episode of major depression every year.

5 May 2010

Clinical Trial News and Research

Cohera Medical reports top-line results from Tissuglu clinical trial

CSI fiscal third-quarter revenue increases 9% to $16.5 million

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416

Jazz Pharmaceuticals reports 59% increase in first-quarter 2010 revenue

GeoVax Labs reports net loss of $690,789 for first-quarter 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

Cardiogenesis reports 13% increase in first-quarter 2010 revenue

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Rockwell Medical first-quarter sales up 17.1%

STEM reports net loss of $6,124,000 for first-quarter 2010: MicroStockProfit.com

BioClinica reports service revenues of $14,746,000 for first-quarter 2010

Canadian Cancer Society awards London scientists new funds for innovative research

Three Hamilton scientists receive cancer research grants from Canadian Cancer Society

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News